Ovarian cancer affects over 22,000 women annually in the U.S., yet only 20% of cases are caught early. With no reliable ...

Teddi Mellencamp, who is battling stage four melanoma, revealed that her doctors have given her 50/50 odds of beating her ...

This year, researchers Megan Shen, PhD, and Mary L. “Nora” Disis, MD, of Fred Hutch Cancer Center and UW Medicine ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

The cancer came back at the end of May 2024. I started a new treatment called Elahere, which is a targeted therapy that was approved specifically for ovarian cancer in 2023. Right now, I’m having what ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.